Home » Pharmacology » Enzyme-Linked Receptors » Receptor Tyrosine Kinases (RTKs) » EGFR » HDS 029

HDS 029

Cat. No. 2646

Price and Availability

For HDS 029 pricing & availability please select your country from the drop down menu:
Submit

By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Chemical Name: N-(4-[(-3-Chloro-4-fluorophenyl)amino]pyrido[3,4-d]pyrimidin-6-yl-2-butynamide

Biological Activity

Potent inhibitor of the ErbB receptor family (IC₅₀ values are 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2 respectively). Inhibits EGF-induced erbB1 autophosphorylation in NIH3T3 cells and heregulin-stimulated ErbB autophosphorylation in MDA-MB-453 human breast carcinoma cells (IC₅₀ values are 2.5 and 24 nM respectively).

Technical Data

M.Wt:

355.76

Formula:

C₁₇H₁₁ClFN₅O

Solubility:

Soluble to 25 mM in DMSO

Purity:

>97 %

Storage:

Store at -20°C

CAS No:

881001-19-0

The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.

Resources

Certificate of Analysis / Safety Data Sheet

Certificate of Analysis: View current batch

Safety Data Sheet: View Safety Data Sheet

References

Klutchko et al (2006) Tyrosine kinase inhibitors. 19. 6-alkynamides of 4-anilinoquinazolines and 4-aniliopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. J.Med.Chem. 49 1475. PMID: 16480284.

If you know of a relevant citation for this product please let us know.

View Related Products by Target

Angiogenesis EGFR

Growth Factor Receptors Receptor Tyrosine Kinases (RTKs)

Keywords: HDS 029, supplier, Potent, inhibitors, ErbB, receptor, family, Epidermal, Growth, Factors, Receptors, Her, EGFR, Receptor, Tyrosine, Kinases, RTKs, HDS029

Quick Order

Find multiple products by catalog number

Cancer Research Guide

Request your free copy

Highlights over 350 products for cancer research. Request a copy or view PDF today.

Kinases Product Listing

Highlights over 350 products for kinase research. Request a copy or view PDF today.

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Some of the most potent
kinase inhibitors all on one plate

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

VEGF Pathway & Anti-Angiogenic Therapy

Written by N. Ferrara & Y. Crawford

A summary of antiangiogenic therapies targeting the VEGF pathway and the mechanisms of therapy resistance.

Therapeutic Strategies in Schizophrenia

Written by J. Lieberman

'Schizophrenia - Emerging Targets and Therapeutic Strategies' provides a summary of the targets and pathways representing the most promising strategies to pursue for novel drug development.